logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of diffuse large B-cell lymphoma

< Back

Polatuzumab vedotin in combination with rituximab and bendamustine for the treatment of diffuse large B-cell lymphoma

Drugs

Cancer and Palliative Care

November 2018


Polatuzumab vedotin in combination with rituximab and bendamustine is in clinical development for previously treated adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are not candidates for hematopoietic stem cell transplant. DLBCL is a cancer affecting a type of white blood cells called lymphocytes or B-cells. It is the most common form of non-Hodgkin lymphoma among adults, though it can also occur in children and young adults in rare cases. DLBCL is an aggressive cancer and although it can be cured in more than half of people affected, it remains a serious and life threatening disease, particularly when it relapses or does not respond to treatment.
Polatuzumab vedotin is a first-in-class antibody drug specifically developed for the treatment of cancers that affect the blood and lymph system. It is a monoclonal antibody that acts by selectively binding to CD79b, a protein which is abundantly expressed on the surface of B-cells. It is administered as an intravenous infusion, absorbed by the cancer cells and the chemotherapy agent linked to the antibody releases inside the cancer cells and destroys them. Adding polatuzumab vedotin to bendamustine with rituximab may improve effectiveness in patients whose disease had come back or in whom other treatment had not worked well enough.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts